Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Analysis supports ensifentrine’s efficacy in COPD as monotherapy and on top of standard of care treatment in patients who remain symptomatic Six abstracts accepted demonstrating ensifentrine’s...
-
Reported positive Phase 2b results in symptomatic patients with moderate to severe COPD with nebulized ensifentrine Reported positive efficacy and safety with single dose pMDI ensifentrine U.S. FDA...
-
LONDON, April 23, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that...
-
LONDON, April 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
-
LONDON, April 08, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...
-
Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation...
-
Statistically significant and clinically meaningful improvements in lung function Ensifentrine has now demonstrated positive efficacy and safety in COPD patients via three widely used inhalation...
-
LONDON, March 20, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
-
LONDON, March 16, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing...
-
LONDON, March 05, 2020 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...